Propanc Biopharma's PRP Shows Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Models

  • Propanc Biopharma published a peer-reviewed pilot study in Scientific Reports demonstrating PRP's anti-tumor efficacy in pancreatic and ovarian cancer models.
  • PRP reduced tumor weight by 85.9% in a pancreatic cancer model and ~50% in an ovarian cancer model.
  • The study showed PRP's anti-angiogenic, anti-metastatic, and EMT reversal effects across 24 human cancer cell lines.
  • In a UK Specials Scheme program, 41.3% of patients with advanced cancers survived longer than predicted.

Propanc Biopharma's PRP formulation targets key drivers of tumor progression, offering a non-cytotoxic approach for advanced cancers. The study's results position PRP as a potential differentiated therapy in areas of high unmet need, such as pancreatic and ovarian cancer. The biopharmaceutical sector continues to seek innovative treatments for metastatic and recurrent cancers, and Propanc's data could attract investor and partner interest.

Clinical Development
How Propanc will advance PRP into later-stage clinical trials and secure regulatory approvals.
Market Positioning
Whether PRP can differentiate itself in the competitive landscape of cancer therapies.
Commercialization Strategy
The pace at which Propanc can bring PRP to market for pancreatic and ovarian cancer indications.